Literature DB >> 9129149

Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line.

H Chen1, Y Ke, A J Oates, R Barraclough, P S Rudland.   

Abstract

Benign rat mammary epithelial cells transfected with restriction enzyme-fragmented DNA from a human malignant metastatic cell line (Ca2-83) produces transfectants that yield metastatic tumours in syngeneic rats. The six metastasis-inducing DNAs (Met-DNAs) that have been isolated from such transfectants are subgene in size and do not code for any expressed mRNAs, but correspond to potential regulatory regions of human DNA from malignant, metastatic cells. In pilot studies the one Met-DNA tested is detectable in some human breast tumours but not in normal tissue. Transfection of all six Met-DNAs singly into the benign mammary epithelial cells causes enhanced expression of osteopontin, whilst transfection of cDNA for osteopontin also induces the metastatic state. These results show that short regulatory DNAs exist in human cancer cells that can induce metastatic spread via a common effector gene, osteopontin, in model rat mammary cell lines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129149     DOI: 10.1038/sj.onc.1200993

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer.

Authors:  Guoxin Zhang; Bin He; Georg F Weber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

2.  Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells.

Authors:  Hongtao Guo; Carlos E Marroquin; Philip Y Wai; Paul C Kuo
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

3.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.

Authors:  Hui Zhang; Qing-Hai Ye; Ning Ren; Lei Zhao; Yan-Fang Wang; Xin Wu; Hui-Chuan Sun; Lu Wang; Bo-Heng Zhang; Yin-Kun Liu; Zhao-You Tang; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

4.  Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1.

Authors:  Jintang Sun; Alei Feng; Songyu Chen; Yun Zhang; Qi Xie; Meixiang Yang; Qianqian Shao; Jia Liu; Qifeng Yang; Beihua Kong; Xun Qu
Journal:  Cell Mol Immunol       Date:  2013-02-18       Impact factor: 11.530

Review 5.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

6.  The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma.

Authors:  Jian Sun; Hong-Mei Xu; Hai-Jun Zhou; Qiong-Zhu Dong; Yue Zhao; Li-Yun Fu; Zhen-Yu Hei; Qing-Hai Ye; Ning Ren; Hu-Liang Jia; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 7.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

8.  Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Authors:  Jin-Cai Wu; Bing-Sheng Sun; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-16       Impact factor: 4.553

Review 9.  Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.

Authors:  David T Denhardt; Devra Mistretta; Ann F Chambers; Shuba Krishna; Joseph F Porter; Srilatha Raghuram; Susan R Rittling
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Generation of metastatic variants by transfection of a rat non-metastatic epithelial cell line with genomic DNA from rat prostatic carcinoma cells.

Authors:  Y Ke; C Beesley; P Smith; R Barraclough; P Rudland; C S Foster
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.